TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer

Translational Breast Cancer Research Consortium (TBCRC)

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Fingerprint

Dive into the research topics of 'TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences